ProKidney Corp Ordinary Shares - Class A PROK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PROK is a good fit for your portfolio.
News
-
ProKidney to Participate in the Jefferies Global Healthcare Conference
-
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
-
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
-
Wolf Popper LLP Announces Investigations on Behalf of Investors in Materially Underperforming Special Purpose Acquisition Companies
-
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
-
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Trading Information
- Previous Close Price
- $4.20
- Day Range
- $3.27–4.26
- 52-Week Range
- $1.12–13.51
- Bid/Ask
- $3.46 / $3.64
- Market Cap
- $222.45 Mil
- Volume/Avg
- 565,687 / 796,877
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 4.26%
Company Profile
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 163
- Website
- https://www.prokidney.com
Comparables
Valuation
Metric
|
PROK
|
KROS
|
ISEE
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 3.68 | 11.49 |
Price/Sales | — | 6,189.52 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
PROK
KROS
ISEE
Financial Strength
Metric
|
PROK
|
KROS
|
ISEE
|
---|---|---|---|
Quick Ratio | 17.14 | 23.73 | 15.24 |
Current Ratio | 17.62 | 24.74 | 15.53 |
Interest Coverage | −13,702.00 | — | — |
Quick Ratio
PROK
KROS
ISEE
Profitability
Metric
|
PROK
|
KROS
|
ISEE
|
---|---|---|---|
Return on Assets (Normalized) | −25.93% | −35.62% | −42.04% |
Return on Equity (Normalized) | — | −39.15% | −50.62% |
Return on Invested Capital (Normalized) | −32.20% | −41.95% | −46.07% |
Return on Assets
PROK
KROS
ISEE
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rfwpfjsfcy | Fzkk | $590.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dmwlqzzrg | Hyxwcfd | $113.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bvldxhvz | Dlsmnf | $106.5 Bil | |
MRNA
| Moderna Inc | Lzytffk | Tbnpl | $58.7 Bil | |
BNTX
| BioNTech SE ADR | Jsshcpsc | Jctb | $23.8 Bil | |
ARGX
| argenx SE ADR | Tlvxnzs | Trpv | $21.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zwyntptdp | Jyvbzw | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fyzsmfqyg | Ffxvvsr | $14.1 Bil | |
INCY
| Incyte Corp | Czjgqjyr | Cyttq | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wgpnsptljs | Vqnsk | $12.4 Bil |